Top News

FEATURED

Dr. Vinnicombe: Use Breast MRI Judiciously

CTA interviewed Dr Sarah Vinnicombe about her recent article on the role of breast MRI for breast cancer staging and screening.

Ghost, Honorary Authorship in Cancer Research

Despite widespread stigma and efforts to limit prevalence, ghost and honorary authorship remain widespread in clinical trials.

ALOXI (palonosetron)

For chemotherapy-induced nausea and vomiting.

Immune Checkpoint Inhibitors, NSCLC Management

Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it's unclear the role it will have in the first-line.

Treating TKI-induced Hypertension in RCC

Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.

MM: Minimal Residual Disease and Treatment

A newly released survey of clinical testing finds that widely divergent methodologies for MRD testing remain a continuing challenge.

New Video Series: R/R Hodgkin Lymphoma

Jeffrey Schriber, MD, FRCP, Cancer Transplant Institute of Arizona Oncology Scottsdale, Arizona

Breast Cancer: Trastuzumab Resistance

Chapter 2: Drs. O’Shaughnessy and Rugo discuss strategies for overcoming trastuzumab resistance.

Endocrine Therapy Continuation Beyond 5 Years?

Using case studies, experts discuss the Breast Cancer Index<sup>SM</sup> as a tool for clinicians and patients considering extended adjuvant endocrine therapy for early-stage ER+ breast cancer.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes

Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes

CTA interviewed Dr Sarah Vinnicombe about her recent article on the role of breast MRI for breast cancer staging and screening.

Ghost and Honorary Authorship in Cancer Research

Ghost and Honorary Authorship in Cancer Research

Despite widespread stigma and efforts to limit prevalence, ghost and honorary authorship remain widespread in clinical trials.

Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC

Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC

Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it's unclear the role it will have in the first-line.

Treating TKI-induced Hypertension in Renal Cell Carcinoma

Treating TKI-induced Hypertension in Renal Cell Carcinoma

Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.

Minimal Residual Disease and Treatment Response in Multiple Myeloma

Minimal Residual Disease and Treatment Response in Multiple Myeloma

A newly released survey of clinical testing finds that widely divergent methodologies for MRD testing remain a continuing challenge.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters